NDA 021113 · Hikma
Pamidronate Disodium
Pamidronate Disodium · Injection
Last checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Mar 4, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
42
4 Phase 3, 1 recruiting
FAERS reports
3,394
3,204 serious, 428 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 4, 2002 Original approval · Type 5 - New Formulation or New Manufacturer ReviewOther Important Information from FDALetter
2 products under this application
- PAMIDRONATE DISODIUM · PAMIDRONATE DISODIUM 30MG/10ML (3MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP1
- PAMIDRONATE DISODIUM · PAMIDRONATE DISODIUM 90MG/10ML (9MG/ML) · INJECTABLE, INJECTION · Prescription · TE AP1
Clinical trials
Interventional ClinicalTrials.gov studies with "Pamidronate Disodium" as an intervention, any sponsor and status, largest first.
- Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/MonthPivotal-lookingCompleted
Nordic Myeloma Study GroupAcademic, hospital or other
NCT00376883 · 500 participants · Start Jan 2000
Drug: pamidronate · For: Multiple Myeloma
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 14 sites in all
- 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone MetastasesPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT02721433 · 263 participants · Start Aug 2016 · Primary completion Sep 2019
Drug: Pamidronate; Denosumab and 1 more · For: Breast Cancer; Prostate Cancer; Metastasis
Sites: Ottawa, Canada
- Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast CancerPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00091832 · 255 participants · Start Sep 2004 · Primary completion Nov 2005
Drug: Denosumab; IV Bisphosphonates · For: Breast Cancer; Metastases; Bone Metastases in Subjects With Advanced Breast Cancer
- Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate CancerPivotal-lookingActive, not recruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04549207 · 240 participants · Start Oct 9, 2020 · Primary completion Apr 17, 2025
Drug: Bone modifying agent · For: Breast Cancer; Castration-resistant Prostate Cancer
Sites: Brampton, Canada; London, Canada; Newmarket, Canada · 5 sites in all
- Bisphosphonate Treatment of Osteogenesis ImperfectaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00063479 · 158 participants · Start Jun 2003 · Primary completion May 2007
Drug: Zoledronic Acid · For: Osteogenesis Imperfecta
Sites: Los Angeles, California; Wilmington, Delaware; Boise, Idaho · 10 sites in all
- Pamidronate Administration in Breast Cancer Patients With Bone MetastasesPivotal-lookingCompleted
Spanish Breast Cancer Research GroupAcademic, hospital or other
NCT00128297 · 152 participants · Start Oct 18, 2000 · Primary completion Jun 4, 2004
Drug: Pamidronate · For: Breast Cancer; Neoplasm Metastasis
Sites: San Sebastián de los Reyes, Spain
- A Prospective, Multicentre, Open-label Randomised Controlled Study to Investigate the Effectiveness of Pamidronate in the Prevention of Bone Loss in de Novo Renal Transplant Patients.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00738257 · 126 participants · Start Jun 2000 · Primary completion Dec 2004
Drug: Pamidronate · For: Bone Loss
Sites: Frimley, United Kingdom
- Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) BisphosphonatesPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT00104650 · 111 participants · Start Jan 2005 · Primary completion Jan 2008
Drug: IV Bisphosphonate q 4 weeks · For: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer; Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- osteonecrosis534
- osteonecrosis of jaw435
- pain421
- bone disorder173
- nausea170
- tooth extraction168
- fatigue154
- diarrhoea149
- malignant neoplasm progression146
- drug ineffective138
- pyrexia138
- infection133
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 134 |
| 2005 | 252 |
| 2006 | 193 |
| 2007 | 151 |
| 2008 | 182 |
| 2009 | 269 |
| 2010 | 399 |
| 2011 | 243 |
| 2012 | 209 |
| 2013 | 56 |
| 2014 | 47 |
| 2015 | 54 |
| 2016 | 78 |
| 2017 | 100 |
| 2018 | 125 |
| 2019 | 216 |
| 2020 | 185 |
| 2021 | 108 |
| 2022 | 91 |
| 2023 | 100 |
| 2024 | 105 |
| 2025 | 60 |
| 2026 | 37 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pamidronate Disodium (Pamidronate Disodium)
2024 spending
$12K
Beneficiaries
97
287 claims
Per beneficiary
$119
$2.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,773 |
| 2021 | $32,246 |
| 2022 | $30,879 |
| 2023 | $21,537 |
| 2024 | $11,550 |
Part B: Pamidronate Disodium (Pamidronate Disodium) · HCPCS J2430
2024 spending
$21K
Beneficiaries
281
786 claims
Per beneficiary
$76
2024 ASP limit $11.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $70,695 |
| 2021 | $52,084 |
| 2022 | $44,697 |
| 2023 | $33,279 |
| 2024 | $21,383 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of pharmacological agents on relapse following orthodontic tooth movement.
Veginadu P, Tavva SR, Muddada V, et al. · Angle Orthod 2020 · Systematic Review
- Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis.
Wang Y, Tang Z, Meng R, et al. · Ann Palliat Med 2021 · Meta-Analysis, Systematic Review
- Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Gucalp R, Ritch P, Wiernik PH, et al. · J Clin Oncol 1992 · Clinical Trial, Comparative Study
- Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
Yang L, Du S · Medicine (Baltimore) 2015 · Meta-Analysis
- Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Ibrahim NK, Sahin AA, Dubrow RA, et al. · Lancet 2000 · Clinical Trial, Clinical Trial, Phase I
- Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Weinfurt KP, Castel LD, Li Y, et al. · Med Care 2004 · Clinical Trial, Comparative Study
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.